Aquestive Therapeutics (AQST) Long-Term Debt Issuances (2019 - 2026)

Aquestive Therapeutics' Long-Term Debt Issuances history runs 6 years deep, the most recent figure standing at $8000.0 for Q1 2026.

• On a quarterly basis, Long-Term Debt Issuances rose 33.33% year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $14000.0, a 99.63% decrease from a year earlier, with the FY2025 full-year figure at $26000.0, up 13.04% from the prior year.
• Long-Term Debt Issuances improved to $8000.0 in Q1 2026 per AQST's latest filing, from $6000.0 in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $9.1 million in Q1 2023 and bottomed at -$9.1 million in Q2 2023.
• The 4-year median for Long-Term Debt Issuances is $8000.0 (2026), against an average of $763800.0.
• Across the five-year window, Long-Term Debt Issuances plunged 338.79% in 2023 and soared 33.33% in 2026, its largest moves.
• Year by year, Long-Term Debt Issuances stood at $3.8 million in 2022, then plunged by 338.79% to -$9.1 million in 2023, then surged by 100.07% to $6000.0 in 2025, then surged by 33.33% to $8000.0 in 2026.
• Per Business Quant, the three latest AQST Long-Term Debt Issuances figures stand at $8000.0 (Q1 2026), $6000.0 (Q1 2025), and -$9.1 million (Q2 2023).